Table 2. Patient characteristics and treatment characteristics at first line therapy according to whether women had received tranexamic acid early (within one hour after the start of first line therapy) or not early (later and no tranexamic acid).
| Early TXA n = 247 |
Late/No TXA n = 984 |
|
|---|---|---|
| Maternal characteristics | ||
| Age, years* | 33 (29–36) | 31 (28–35) |
| BMI (kg/m2)* | 23 (21–26) | 23 (21–27) |
| Ethnicity† | ||
| Caucasian | 181 (73) | 698 (71) |
| Non-Caucasian | 53 (21) | 219 (22) |
| Unknown | 13 (5) | 67 (7) |
| Obstetric Characteristics | ||
| Nulliparity† (yes) | 133 (54) | 511 (52) |
| Gestational age (weeks)* | 40 (38–41) | 40 (38–41) |
| Labour characteristics | ||
| Mode of delivery† | ||
| Vaginal | 175 (71) | 769 (78) |
| Caesarean section |
71 (29) | 208 (21) |
| Transfer to hospital No transfer (birth with midwife) Postpartum transfer |
162 (66) 34 (14) |
647 (66) 125 (13) |
| Primary cause of bleeding† | ||
| Uterine atony | 168 (68) | 621 (63) |
| Retained placenta | 39 (16) | 176 (18) |
| Other | 40 (16) | 187 (19) |
| Placentation† | ||
| Abnormal localisation placenta | 34 (14) | 124 (13) |
| Pathological ingrowth placenta | 22 (9) | 94 (10) |
| Treatment characteristics at first line therapy | ||
| Fibrinogen-previously† | 4 (2) | 3 (0) |
| recombinantFVIIa-previously† | 0 (0) | 0 (0) |
| Estimated blood loss previously, ml* | 1300 (450–1933) | 800 (150–1400) |
| Bleeding rate, ml/min* | 24 (14–43) | 19 (9.2–38) |
| Shock any time before first line therapy † | 76 (31) | 203 (21) |
* median and (IQR)
† number and %